These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 2146049

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Exacerbation of porokeratosis during etretinate therapy.
    Knobler RM, Neumann RA.
    Acta Derm Venereol; 1990; 70(4):319-22. PubMed ID: 1977257
    [Abstract] [Full Text] [Related]

  • 4. Response of PUVA-induced keratoses to etretinate.
    Hudson-Peacock MJ, Angus B, Farr PM.
    J Am Acad Dermatol; 1996 Jul; 35(1):120-3. PubMed ID: 8682951
    [No Abstract] [Full Text] [Related]

  • 5. Etretinate in the treatment of disseminated porokeratosis of Mibelli.
    Hacham-Zadeh S, Holubar K.
    Int J Dermatol; 1985 May; 24(4):258-60. PubMed ID: 4008157
    [Abstract] [Full Text] [Related]

  • 6. Etretinate treatment in disseminated porokeratosis.
    Danno K, Yamamoto M, Yokoo T, Ohta M, Ohno S.
    J Dermatol; 1988 Oct; 15(5):440-4. PubMed ID: 3065386
    [No Abstract] [Full Text] [Related]

  • 7. [A case of superficial disseminated actinic porokeratosis treated with an aromatic retinoid].
    Ludera-Zimoch G, Rubisz-Brzezińska J.
    Przegl Dermatol; 1989 Oct; 76(1):54-7. PubMed ID: 2813819
    [Abstract] [Full Text] [Related]

  • 8. Treatment of disseminated superficial actinic porokeratosis with a new aromatic retinoid (Ro 10-9359).
    Kariniemi AL, Stubb S, Lassus A.
    Br J Dermatol; 1980 Feb; 102(2):213-4. PubMed ID: 7387874
    [No Abstract] [Full Text] [Related]

  • 9. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.
    Lacouture ME, Desai A, Soltani K, Petronic-Rosic V, Laumann AE, Ratain MJ, Stadler WM.
    Clin Exp Dermatol; 2006 Nov; 31(6):783-5. PubMed ID: 16824050
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Disseminated superficial actinic porokeratosis with hyperkeratotic lesions.
    Schuldenfrei JA, Fix LW.
    Cutis; 1984 Apr; 33(4):369-70. PubMed ID: 6723369
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Unusual side effects in patients with psoriatic erythroderma treated with etretinate (RO 10-9359)].
    Castel T, Castro J, Lecha M, Mascaró JM.
    Med Cutan Ibero Lat Am; 1986 Apr; 14(2):83-6. PubMed ID: 2943953
    [Abstract] [Full Text] [Related]

  • 19. Preventative effect of etretinate therapy on multiple actinic keratoses.
    Watson AB.
    Cancer Detect Prev; 1986 Apr; 9(1-2):161-5. PubMed ID: 3524840
    [Abstract] [Full Text] [Related]

  • 20. [Treatment of hyperkeratotic dermatoses with an oral aromatic retinoid (Ro 10-9359)].
    Pehamberger H, Esca SA, Holubar K.
    Z Hautkr; 1980 Jan 15; 55(2):68-78. PubMed ID: 7405336
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.